Added to YB: 2026-06-18
Pitch date: 2026-06-16
SANA [bullish]
Sana Biotechnology, Inc.
Author Info
Clinical Catalysts breaks down the science and strategy behind pharma market movers. Sign up for the newsletter.
Company Info
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States.
Market Cap
$848.7M
Pitch Price
N/A
Price Target
14.40 (+409%)
Dividend
N/A
EV/EBITDA
-6.30
P/E
-3.08
EV/Sales
N/A
Sector
Biotechnology
Category
growth
The $800M Biotech Trying To Rewrite Cell Therapy (SANA)
SANA: Clinical-stage biotech ($790M cap, $2.84) w/ Hypoimmune Platform engineering cells to evade immune rejection w/o immunosuppression. UP421 T1D data (NEJM-published) showed 14+ mo graft survival, insulin production. Cash $128.9M pro forma, runway into 2027. Catalysts: SC451 IND/Ph1, SG293 first-in-human H2 2026. Risk-weighted EV ~$5.03/share (+77%); bull case $10.80-14.40 (+280-407%). Risks: early data, platform validation, dilution.
Read full article (9 min)